Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Barclays PLC (BCS) vs Centene Corp (CNC) Price & Performance

Barclays PLCTrade
Centene CorpTrade

Price performance (Past 24H)

Key statistics

Barclays PLC vs Centene Corp — how do they compare? Barclays PLC trades at $27.84 (market cap $92.56B), while Centene Corp trades at $66.06 (market cap $33.93B). The key difference: Barclays PLC is far larger — about 2.7× Centene Corp's market cap, and Barclays PLC pays a 1.67% dividend while Centene Corp pays none. Which is the better fit depends on your goals.

BCSCNC
Market Cap
$92.56B$33.93B
Sector
FinancialsHealth
52-Week High
$28.41$68.72
52-Week Low
$18.48$25.21
Dividend Yield
1.67%
Enterprise Value
$26.56B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Barclays PLC

Barclays PLC (BCS) trades at $27.29, down 0.69% on the day, near its 52-week high of $28.43. The stock shows strong fundamental momentum with revenue rising to $29.14B in 2025 and net income reaching $7.17B, supported by three consecutive quarterly EPS beats. Technical indicators signal a bullish trend, while analyst sentiment remains positive with 68% buy ratings. Recent news highlights ongoing legal investigations but also underscores the bank's role in market analysis and product innovation.

The outlook for BCS is cautiously optimistic, driven by solid earnings growth and attractive valuation metrics like a P/E of 11.91 and P/B of 0.91. Key risks include potential legal liabilities from securities investigations and macroeconomic sensitivity. Investors should weigh the strong analyst support against these headwinds for balanced decision-making.

Centene Corp

Centene Corporation (CNC) trades at $68.29, up 1.4% with strong technical momentum and bullish moving average signals. The stock shows impressive 66% YTD gains, supported by recent contract renewals and margin recovery initiatives. Despite negative 2025 net income of -$6.67B, valuation metrics remain attractive with P/E of 8.06 and P/S of 0.17. Analyst consensus is strongly bullish with 61% buy ratings and $66.07 price target.

Centene presents a compelling value opportunity with low valuation multiples and strong operational cash flow of $5.09B. Key risks include ongoing margin pressure and Medicaid contract dependency. The company's AI-driven cost controls and recent Illinois Medicaid renewal provide catalysts for earnings recovery, though healthcare regulatory changes remain a concern for long-term stability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Barclays PLC

Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments

Read more on BCS

About Centene Corp

Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.

Read more on CNC